I. MODIFIED AGREEMENTS | |||
Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
| |||
Ardais Corp.* |
Aventis SA (France) |
Expanded deal allowing Aventis to use Ardais technology in evaluating biological targets |
Ardais will combine its BIGR Library of tissues and associated patient data with its immunohistochemistry profiling in the effort; terms were not disclosed (4/6) |
Dharmacon Inc.* |
Bayer Pharmaceuticals Corp. |
Expanded agreement for the supply of custom siRNA reagents for use in Bayer target validation and drug discovery |
Dharmacon will supply siRNA reagents for about 4,000 gene targets; terms of the deal were not disclosed (3/2) |
Gene Logic Inc. (GLGC) |
Sankyo Co. Ltd. (Japan) |
Multiyear renewal agreement for Sankyo to continue using certain parts of Gene Logic's information services for R&D |
Sankyo reduced is access to certain technologies in renewing the deal struck in 2001; terms were not disclosed (4/5) |
Gene Logic Inc. (GLGC) |
Boehringer Ingelheim International GmbH (Germany) |
BI renewed deal to use Gene Logic's information services in R&D programs |
BI retains use of the GeneExpress Suite of Data for a multiyear period; terms of the deal were not disclosed (2/20) |
Genmab A/S (Denmark; CSE:GEN) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Roche selected two antibodies as candidates for clinical development under their collaboration |
Specific details related to the actions were not disclosed; Genmab can earn milestone and royalty payments in the alliance (3/19) |
Isotechnika Inc. (Canada; TSE:ISA) |
Hoffmann-La Roche Inc. |
Isotechnika will take over development of transISA247 in renal transplantation |
Roche still can get all rights in transplant indications through Phase II trials by paying an option fee, milestones and 70% of development costs; Isotechnika would get royalties and retains rights outside transplantation (4/20) |
LION Bioscience AG (Germany; LEON) |
GlaxoSmithKline plc (UK) |
GSK renewed its license to LION's SRS data-integration platform |
Terms of the deal were not disclosed (4/7) |
MorphoSys AG (Germany; FSE:MOR) |
Centocor Inc. (unit of Johnson & Johnson) |
MorphoSys will generate antibodies against a target selected by Centocor under their December 2000 collaboration |
MorphoSys stands to receive undisclosed license fees, milestone payments and sales royalties; MorphoSys already generated two antibodies under the deal (3/8) |
Serologicals Corp. (SERO) |
Novo Nordisk A/S (Denmark) |
Expanded deal for worldwide distribution of human recombinant insulin for use in cell culture media markets |
The deal on distributing Serologicals' products was extended through 2006; terms were not disclosed (3/9) |
Transkaryotic Therapies Inc. (TKTX) |
Aventis Pharmaceuticals Inc. |
Aventis returned to TKT all rights to Dynepo in Europe and everywhere outside the U.S. |
TKT will pay Aventis a scaled royalty on Dynepo sales; Aventis obtained an option on certain TKT gene-therapy technology for one year; TKT is responsible for any legal expenses in Europe over the product and half of any such expenses in the U.S. (3/26) |
Tranzyme Inc.* |
Becton, Dickinson & Co. |
Expanded deal under which BD will continue to get access to Tranzyme's gene delivery and expression technologies |
Companies also will explore use of technologies to specific cell types of interest to BD, in exchange for R&D funding for Tranzyme; BD would pay royalties on sales of any resulting products (3/2) |
Tularik Inc. (TLRK) |
Sankyo Co. Ltd. (Japan) |
Sankyo expanded the collaboration by selecting up to four GPCR targets for further research for one year |
Tularik is entitled to further financial support, as well as potenial milestones and royalties on any resulting products; the companies are sharing costs and profits from the deal (3/8) |
Vivus Inc. (VVUS) |
Tanabe Seikayu Co. Ltd. (Japan) |
Vivus gained an $8.5M line of credit from Tanabe for development of avanafil (TA-1790) |
Vivus licensed the erectile dysfunction product from Tanabe in 2001; the product is in Phase II trials (4/6) |
II. TERMINATED AGREEMENTS | |||
Guilford Pharmaceuticals Inc. (GLFD) |
Pfizer Inc. |
Guilford regained all rights to NAALADase inhibitors that were covered under their May 2003 collaboration |
Pfizer ended the deal one day before it would have owed a $10M milestone payment; Guilford, which received $5M in the deal, will seek a new partner (3/30) |
Maxim Pharmaceuticals Inc. (MAXM) |
Shire Pharmaceuticals Group plc (UK) |
Maxim regained rights to the MX2105 series of vascular targeting agents for cancer |
BioChem Pharma licensed the series in 2000; Shire, which acquired BioChem, was getting out of oncology; Shire would earn milestone and royalty payments if any drugs from the series are developed (3/17) |
PPL Therapeutics plc (UK; LSE:PPH) |
Bayer Biological Products |
Companies terminated their agreement for development of recombinant alpha-1 antitrypsin |
The move followed a June 2003 decision to put the program on hold; Bayer gets a royalty-free right to develop the product later for congenital deficiency, cystic fibrosis or chronic obstructive pulmonary disease, and PPL retains rights elsewhere (2/16) |
Regeneron Pharmaceuticals Inc. (REGN) |
Novartis Pharma AG (Switzerland) |
Novartis decided to forgo its rights under the collaboration to develop the Interleukin-1 Trap product, after Regeneron would not revise terms following a Phase II trial that missed its primary endpoint |
Novartis has paid about $102M to date in up- front and milestone payments, and development expenses; Regeneron plans to move the product into a Phase IIb trial in rheumatoid arthritis in 2H:04; each firm retains rights to collaborate on other IL-1 antagonists being developed independently that are in earlier-stage development (2/27); Novartis agreed to pay $42.75M to satisfy its remaining obligation to fund development costs (4/1) |
Sepracor Inc. (SEPR) |
Ross Products Division of Abbott Laboratories |
The co-promotion deal for Xopenex will be terminated effective Dec. 31, 2004; the product is a bronchodilator |
Sepracor is ending the deal as it increases its sales force; it will pay Ross $30M by the end of 2005 and $3M by the end of 2006 (3/25) |
SynX Pharma Inc. (Canada; TSE:SYY) |
Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson) |
Synx reacquired rights to technology for diagnosing Alzheimer's licensed to Ortho in October 2002 |
Ortho terminated the deal and returned all rights to SynX, which said it intends to continue development (3/5) |
Targeted Genetics Corp. (TGEN) |
Elan Corp. plc (Ireland) |
Companies formally ended their Emerald Gene Systems Ltd. joint venture |
Work in the venture had ended in 2002; Elan converted its Series B preferred stock into 4.3M TGEN shares (4/6) |
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange. |